| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | 1 | Y | 0 CD19 CAR T-cell Therapy | 396 | 240 | 92 | 55 | 27 | 8 | 3 | 06/12/2023 | 147 | 45 |
| 240 | 92 | 55 | 27 | 8 | 3 | |||||||||
| 2 | Y | 1 Mosunetuzumab | 13 | 5 | 4 | 2 | 0 | 0 | 06/12/2023 | |||||
| 2 Polatuzumab | 12 | 4 | 2 | 1 | 0 | 0 | ||||||||
| 3 Mosunetuzumab + Polatuzumab | 13 | 5 | 4 | 2 | 1 | 0 | ||||||||
| 4 Observation | 14 | 7 | 4 | 3 | 1 | 1 | ||||||||
| 52 | 21 | 14 | 8 | 2 | 1 | |||||||||
| 3 | Y | 5 Mosunetuzumab + Polatuzumab | 4 | 1 | 0 | 0 | 0 | 0 | 06/12/2023 | |||||
| 4 | 1 | 0 | 0 | 0 | 0 | |||||||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | 1 | T | 1 Tazemetostat (Arm 1) Dose Level 1 | 241 | 7 | 0 | 0 | 0 | 0 | 0 | 09/26/2023 | 141 | 40 | |
| 10 Tazemetostat (Arm 1) Dose Level 1 | 6 | 6 | 0 | 0 | 0 | 0 | ||||||||
| 11 Tazemetostat (Arm 1) Dose Level 2 | 5 | 5 | 3 | 0 | 0 | 0 | ||||||||
| 13 Zanubrutinib (Arm 3) Dose Level 2 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||||
| 4 Zanubrutinib (Arm 3) Dose Level 1 | 10 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 5 Zanubrutinib (Arm 3) Dose Level 2 | 10 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 39 | 12 | 3 | 0 | 0 | 0 | |||||||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | 1 | Y | 1 Rituximab | 600 | 194 | 124 | 71 | 37 | 9 | 1 | 10/23/2024 | 259 | 90 | |
| 2 Mosunetuzumab | 196 | 126 | 73 | 41 | 12 | 2 | ||||||||
| 390 | 250 | 144 | 78 | 21 | 3 | |||||||||
| Yes | A051902-PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P | 1 | E | Total Registrations | 19 | 1 | 0 | 0 | 0 | 0 | 10/14/2023 | 223 | 80 | |
| 19 | 1 | 0 | 0 | 0 | 0 | |||||||||
| A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub | 1 | E | Total Registrations | 35 | 16 | 8 | 2 | 0 | 0 | 01/03/2024 | 237 | 78 | ||
| 35 | 16 | 8 | 2 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 16 | 6 | 3 | 2 | 0 | 0 | 01/03/2024 | |||||
| 16 | 6 | 3 | 2 | 0 | 0 | |||||||||
| AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | 1 | E | Total Registrations | 110 | 46 | 26 | 13 | 3 | 0 | 08/15/2023 | 330 | 131 | ||
| 110 | 46 | 26 | 13 | 3 | 0 | |||||||||
| 2 | E | Total Registrations | 96 | 46 | 22 | 11 | 3 | 0 | 08/15/2023 | |||||
| 96 | 46 | 22 | 11 | 3 | 0 | |||||||||
| No | EA4231-Lymph, DL B-Cell, Ven+Ib+Pred+Ob+Rev | 1 | E | Total Registrations | 1 | 1 | 1 | 0 | 0 | 0 | 03/30/2026 | 35 | 9 | |
| 1 | 1 | 1 | 0 | 0 | 0 | |||||||||
| EA4232-Lymph, Peri T Cell, Auto Stem | 1 | E | Total Registrations | 2 | 2 | 0 | 0 | 0 | 0 | 09/15/2025 | 130 | 37 | ||
| 2 | 2 | 0 | 0 | 0 | 0 | |||||||||